ALLO
Allogene Therapeutics, Inc.Marquee-fund ownership over time
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Renaissance Technologies | Q3 2024(8Q snapshot) | 7Q | $2.32 | $1.94 | -16% |
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $2.25 | $1.94 | -14% |
| Two Sigma Investments | Q3 2024(8Q snapshot) | 7Q | $2.25 | $1.94 | -14% |
| D.E. Shaw re-entered | Q3 2024(8Q snapshot) | 7Q | $2.25 | $1.94 | -14% |
| AQR Capital Management re-entered | Q3 2024(8Q snapshot) | 7Q | $2.25 | $1.94 | -14% |
| Millennium Management re-entered | Q3 2024(8Q snapshot) | 7Q | $2.25 | $1.94 | -14% |
| Point72 Asset Management | Q1 2026(8Q snapshot) | 1Q | $2.16 | $1.94 | -10% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| D1 Capital Partners | Q3 2020 | Q4 2020 | → $33 | -11% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Allogene Therapeutics, Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Apr 23, 2026 — the most recent Form 4 on file — not from today.
- Form 40001835208-26-000003Apr 23, 2026
- Form 40002057918-26-000007Apr 2, 2026
- Form 40001737287-26-000015Mar 18, 2026
- Form 40001737287-26-000013Mar 18, 2026
- Form 40002057918-26-000003Mar 4, 2026
- Form 40001737287-26-000011Feb 4, 2026
- Form 40001737287-26-000009Feb 4, 2026
- Form 40001737287-26-000007Feb 4, 2026
- Form 40001362155-26-000002Feb 4, 2026
- Form 40001737287-26-000005Feb 4, 2026
- Form 40001737287-26-000002Feb 4, 2026
- Form 40001296549-26-000002Feb 4, 2026
- Form 40001851044-26-000003Jan 23, 2026
- Form 40001221355-25-000005Dec 22, 2025
- Form 40001737287-25-000094Nov 19, 2025
Fundamentals
XBRL · Allogene Therapeutics, Inc.Annual figures sourced directly from Allogene Therapeutics, Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Allogene Therapeutics, Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventMay 28, 2026
- 10-QQuarterly reportMay 13, 2026
- 8-KMaterial eventMay 13, 2026
- DEF 14AProxy statementApr 30, 2026
- 8-KMaterial eventApr 15, 2026
- 8-KMaterial eventApr 13, 2026
- 8-KMaterial eventApr 13, 2026
- 10-KAnnual reportMar 12, 2026
- 8-KMaterial eventMar 12, 2026
- 10-QQuarterly reportNov 6, 2025
- 8-KMaterial eventNov 6, 2025
- 8-KMaterial eventOct 14, 2025
- 10-QQuarterly reportAug 13, 2025
- 8-KMaterial eventAug 13, 2025
- 8-KMaterial eventAug 1, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| Point72 Asset Management | Q1 2026 | open | $2.16 | $1.94 | -10% |
| D.E. Shaw | Q4 2025 | open | $1.23 | $1.94 | +58% |
| AQR Capital Management | Q2 2025 | open | $1.09 | $1.94 | +78% |
| Millennium Management | Q2 2025 | open | $1.09 | $1.94 | +78% |
| Citadel Advisors | Q3 2024 | open | $2.25 | $1.94 | -14% |
| Two Sigma Investments | Q3 2024 | open | $2.25 | $1.94 | -14% |
| D.E. Shaw | Q3 2024 | Q2 2025 | $2.25 | $1.09 | -52% |
| AQR Capital Management | Q3 2024 | Q1 2025 | $2.25 | $2.04 | -9% |
| Millennium Management | Q3 2024 | Q1 2025 | $2.25 | $2.04 | -9% |
| Renaissance Technologies | Q3 2024 | open | $2.32 | $1.94 | -16% |
| D1 Capital Partners | Q3 2020 | Q4 2020 | $37 | $33 | -11% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.